ICI hypophysitis is more common in males and occurs at an older age than other causes of hypophysitis, although this may reflect the demographics of ICI treatment or underlying tumors [10] Hypophysitis occurs relatively frequently in patients treated using the CTLA4 blocker ipilimumab; the incidence of ICI is nearly 12%. This evidence concerns the gene CTLA4 and hypophysitis.